Incretin-Based Therapies for Type 2 Diabetes
WebcastFaculty
OVERVIEW
Incretin-Based Therapies for Type 2 Diabetes is organized by Pri-Med and will be held during Apr 04, 2017 - Apr 04, 2018.
The target audience for this medical event is Endocrinologists. This CME Conference has been approved with a maximum of 1.00 AMA PRA Category 1 Credits.
Overview :
As the US population with type 2 diabetes mellitus (T2DM) grows, community-based clinicians face challenges in implementing recommendations on individualizing treatment goals and therapeutic regimens. This webcast focuses on efficacy, safety, and prescribing considerations with incretin-based antihyperglycemic medications, including results from cardiovascular outcomes trials and combination formulations with insulin analogs.
Learning Objectives :
• Describe the underlying mechanisms of T2DM, focusing on the pathophysiologic and potentially therapeutic roles of incretin hormone signaling
• Identify comprehensive treatment goals for T2DM that reflect the degree of hyperglycemia, relevant comorbidities, and other patient-specific factors
• Discuss the comprehensive clinical profiles of incretin-based therapies, including the potential benefits and risks of combining these agents with insulin
• Intensify antihyperglycemic regimens with incretin-based therapies to achieve individualized glycemic targets
• Educate patients with T2DM to motivate lifestyle modifications, reduce hypoglycemia risks, and enhance treatment adherence
Additional details will be posted as soon as they are available.
The target audience for this medical event is Endocrinologists. This CME Conference has been approved with a maximum of 1.00 AMA PRA Category 1 Credits.
Overview :
As the US population with type 2 diabetes mellitus (T2DM) grows, community-based clinicians face challenges in implementing recommendations on individualizing treatment goals and therapeutic regimens. This webcast focuses on efficacy, safety, and prescribing considerations with incretin-based antihyperglycemic medications, including results from cardiovascular outcomes trials and combination formulations with insulin analogs.
Learning Objectives :
• Describe the underlying mechanisms of T2DM, focusing on the pathophysiologic and potentially therapeutic roles of incretin hormone signaling
• Identify comprehensive treatment goals for T2DM that reflect the degree of hyperglycemia, relevant comorbidities, and other patient-specific factors
• Discuss the comprehensive clinical profiles of incretin-based therapies, including the potential benefits and risks of combining these agents with insulin
• Intensify antihyperglycemic regimens with incretin-based therapies to achieve individualized glycemic targets
• Educate patients with T2DM to motivate lifestyle modifications, reduce hypoglycemia risks, and enhance treatment adherence
Additional details will be posted as soon as they are available.
SPECIALITIES
Endocrinology, Metabolism and Diabetes
Quick Links